Loading…
← CockpitCompetitor Analysis › 000915.SZ Shandong Wit Dyne Health Co., Ltd. Class AOpen in the cockpit ↗

Shandong Wit Dyne Health Co., Ltd. Class A000915.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum weak 22
Mkt cap
$687M
US dollars, full cap
Free float
68%
of shares outstanding
$/day
$9.87M
20-day average traded
Fwd P/E
9.1×
forward earnings
ROIC−WACC
+10.0 pp
WACC 6.2%
Hurdle
n/a
no reverse DCF
Next earnings
124 days
22 Mar 2027
Close · CNYCN¥19.55
1D+0.7%
1W-0.4%
1M-21.4%
3M-24.7%
6M-31.1%
YTD-40.8%
1Y-43.2%
ATR %3.0%
52w lowhigh45.9% off high

What Shandong Wit Dyne Health does

Employees: 1,719

Shandong Wit Dyne Health at a glance

Size Shandong Wit Dyne Health (000915.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $687M, the 2932nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥19.55 on 18 Nov 2026.

Performance Over six months the shares fell 31.1%, against -7.8% for the median peer and -20.0% for the China market (cap-weighted) — 5th lowest of 21 in its peer set.

Growth Revenue fell 35.8% over the last twelve months (peer median +4.4%); the operating margin is 36.2% (peer median 9.7%).

Valuation It trades at 9.1× forward earnings against a peer median of 17.0× (2nd cheapest of 11).

Capital Return on invested capital runs 10.0 points above its cost of capital (6.2% WACC).

Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 94000915.SZ 71
Six months, rebased to 100: Shandong Wit Dyne Health against the median of its 20 peers (local-currency closes).

Shandong Wit Dyne Health financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.51BCN¥2.20BCN¥2.10BCN¥2.45BCN¥2.31B
Revenue growth—+5%-15%+6%—
Gross profitCN¥1.26BCN¥1.83BCN¥1.71BCN¥2.08BCN¥1.79B
EBITDAn/aCN¥1.24BCN¥1.18BCN¥1.34BCN¥1.21B
Net incomeCN¥284MCN¥535MCN¥516MCN¥585MCN¥527M
Free cash flow-CN¥7.73MCN¥1.25BCN¥915MCN¥1.15BCN¥1.13B
Capital expenditureCN¥15.7MCN¥48.3MCN¥43.6MCN¥50.6MCN¥89.7M
Total debtCN¥0CN¥356,348CN¥2.86MCN¥66,955CN¥9.89M

Quarterly statements and history in the cockpit →

Shandong Wit Dyne Health competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%-20%-10%0%+10%4985600351NVCT688658600829PHIL688488ANNXSPARC45340570SGMTFDC688799600530688566INNOVACAP0005662186000915.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Shandong Wit Dyne Health is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%+300%0×50×100×4985688658PHIL6884884534603998688799688566INNOVACAP000915.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shandong Wit Dyne Health is the large dot.

Shandong Wit Dyne Health competitors and peer comparison

How Shandong Wit Dyne Health compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shandong Wit Dyne Health against its 20 peers (data as of 18 Nov 2026)
Measure000915.SZPeer medianRank in peer set
1-month return-21.4%-2.8%2nd lowest of 21
6-month return-31.1%-7.8%5th lowest of 21
Distance from 52-week high-45.9%-31.1%8th lowest of 21
Revenue growth (TTM)-35.8%+4.4%lowest of 18
Operating margin36.2%9.7%3rd highest of 18
Forward P/E9.1×17.0×2nd cheapest of 11
ROIC minus cost of capital+10.0 pp+0.0 pp3rd highest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shandong Wit Dyne Health 000915.SZChina$687M-31%-36%36%9.1×n/an/a
Earth 4985.TJapan$687M+7%+4%4%18.0×-1.6%-1.8%
Yabao Pharmaceutical 600351.SSChina$678M0%-3%16%n/a-8.3%-2.8%
Nuvectis Pharma NVCTUnited States$698M+91%n/an/an/an/an/a
Youcare Pharmaceutical 688658.SSChina$674M-49%-7%-13%24.9×n/an/a
HPGC Renmintongtai Pharmaceutical 600829.SSChina$701M-6%+4%2%n/a4.0%+5.3%
Philogen PHIL.MIItaly$672M-11%+295%79%10.1×n/an/a
Jiangsu Aidea Pharmaceutical 688488.SSChina$672M-35%+7%8%112.1×31.9%+19.8%
Annexon ANNXUnited States$671M-30%n/an/an/an/an/a
Sun Pharma Advanced Research SPARC.NSIndia$660M+6%+3,141%84%n/an/an/a
Mochida Pharmaceutical 4534.TJapan$714M-3%+16%10%16.1×n/an/a
China Traditional Chinese Medicine 0570.HKHong Kong$716M-31%-16%0%n/an/an/a
Hunan Fangsheng Pharmaceutical 603998.SSChina$719M-1%+12%20%13.7×-4.8%+6.4%
Sagimet Biosciences SGMTUnited States$722M+52%n/an/an/an/an/a
FDC FDC.NSIndia$653M+3%+10%14%n/a25.2%+10.3%
Hunan Warrant Pharmaceutical 688799.SSChina$725M-34%-3%9%47.6×n/an/a
Shanghai Jiaoda Onlly 600530.SSChina$726M-25%-2%-2%n/a42.7%-0.9%
Jiangsu Jibeier Pharmaceutical 688566.SSChina$727M-9%+8%26%11.2×5.9%+11.3%
Innova Captab INNOVACAP.NSIndia$645M+20%+37%12%32.2×27.1%+31.4%
Hainan Haiyao 000566.SZChina$642M-18%-18%-50%n/an/an/a
Luye Pharma 2186.HKHong Kong$736M-32%+3%18%7.1×-11.8%+1.9%

Questions

Which companies are Shandong Wit Dyne Health's closest peers?
The cockpit's peer set: Earth (4985.T), Yabao Pharmaceutical (600351.SS), Nuvectis Pharma (NVCT), Youcare Pharmaceutical (688658.SS), HPGC Renmintongtai Pharmaceutical (600829.SS), Philogen (PHIL.MI), Jiangsu Aidea Pharmaceutical (688488.SS), Annexon (ANNX).
Is Shandong Wit Dyne Health expensive compared with its peers?
On forward p/e it trades at 9.1× against a peer median of 17.0×, 2nd cheapest of 11 in its peer set.
How has Shandong Wit Dyne Health stock performed?
Over six months to 18 Nov 2026 the shares returned -31.1% against -7.8% for the median peer; over one year -43.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.